WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2009056146) PHARMACEUTICAL COMPOSITION COMPRISING GABOXADOL AND AN INHIBITOR OF PATL OR OAT
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2009/056146    International Application No.:    PCT/DK2008/050264
Publication Date: 07.05.2009 International Filing Date: 28.10.2008
IPC:
A61K 31/437 (2006.01), A61K 45/06 (2006.01)
Applicants: H. LUNDBECK A/S [DK/DK]; Ottiliavej 9 DK-2500 Valby (DK) (For All Designated States Except US).
LARSEN, Mie [DK/DK]; (DK) (For US Only).
NIELSEN, Carsten, Uhd [DK/DK]; (DK) (For US Only).
LARSEN, Birger, Brodin [DK/DK]; (DK) (For US Only).
HOLM, Rene [DK/DK]; (DK) (For US Only)
Inventors: LARSEN, Mie; (DK).
NIELSEN, Carsten, Uhd; (DK).
LARSEN, Birger, Brodin; (DK).
HOLM, Rene; (DK)
Common
Representative:
H. LUNDBECK A/S; Ottiliavej 9 DK-2500 Valby (DK)
Priority Data:
PA 2007 01541 29.10.2007 DK (Priority Withdrawn 23.04.2010)
PA 2008 01198 01.09.2008 DK
PA 2008 01443 16.10.2008 DK
Title (EN) PHARMACEUTICAL COMPOSITION COMPRISING GABOXADOL AND AN INHIBITOR OF PATL OR OAT
(FR) COMPOSITION PHARMACEUTIQUE COMPRENANT DU GABOXADOL ET UN INHIBITEUR DE PAT1 OU D'OAT
Abstract: front page image
(EN)The present invention relates to a pharmaceutical composition comprising gaboxadol or a pharmaceutically acceptable salt thereof and one or more inhibitors of PAT1 and/or one or more inhibitors of OAT. The present invention further relates to a pharmaceutical composition comprising from about 0.5 mg to about 50 mg gaboxadol or a pharmaceutically acceptable salt thereof, wherein the composition provides an in vivo plasma profile comprising a mean Tmax which is longer than about 20 minutes.
(FR)La présente invention concerne une composition pharmaceutique comprenant du gaboxadol ou un sel pharmaceutiquement acceptable de ce dernier ainsi qu'un ou plusieurs inhibiteurs de PAT1 et/ou un ou plusieurs inhibiteurs d'OAT. La présente invention concerne en outre une composition pharmaceutique comprenant entre environ 0,5 mg et environ 50 mg de gaboxadol ou d'un sel pharmaceutiquement acceptable de ce dernier, la composition présentant un profil plasmatique in vivo comprenant un Tmax moyen supérieur à environ 20 minutes.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)